Quarterly results can go a long way toward making or breaking a stock. One healthcare company in particular, a biopharmaceutical stock called YS Biopharma (NASDAQ:YS), showed just what kind of impact those numbers can have. Indeed, YS Biopharma stock was up over 41% at one point, although shares have pulled back since.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The firm announced total revenue of approximately $103 million. That’s up 30% against this time last year. Its gross margin came in at just over 76%, and it held cash and cash equivalents of close to $53 million, giving it a solid cushion in case things turn south. The company’s CEO, President, and Director, Dr. David Shao, noted that vaccine revenues were especially on the rise, despite a floundering overall environment. One of YS Biopharma’s specialties is a rabies vaccine, which has delivered solid numbers for the last three years.
That’s not all, though; YS Biopharma also has a PIKA recombinant COVID-19 vaccine in the works, which successfully met endpoints for Phase II / III head-to-head testing. Interim data was taken from the first 300 enrollees and offered results sufficient to declare YS Biopharma’s vaccine an “…effective booster vaccine.”
A look at the past five trading days for YS stock highlights the impact today’s news had on its price. Indeed, shares had initially spiked after the opening bell. Although the stock has given back almost all of the earlier gains, investors are still up almost 7% during this timeframe.
